pandemic influenza vaccine H1N1

The **pandemic influenza vaccine H1N1** refers to monovalent vaccines developed in 2009 to protect against the novel influenza A (H1N1)pdm09 virus during the swine flu pandemic. These inactivated or live attenuated vaccines contain hemagglutinin from the A/California/7/2009 (H1N1) strain, propagated in eggs or Vero cells, and elicit antibodies against viral hemagglutinin to prevent infection. Some formulations, like Pandemrix (GSK), used AS03 adjuvant for dose-sparing; others, like Celvapan, were unadjuvanted. Primarily indicated for active immunization in adults, children, and high-risk groups, with intramuscular administration. Safety concerns included a confirmed association between Pandemrix and narcolepsy in children/adolescents in certain European countries (e.g., Finland, Sweden), but overall benefit-risk remained positive during the pandemic.[1][2][3][4][5]

Brand names

PandemrixCelvapanArepanrixFocetria

Other names

influenza A (H1N1) 2009 monovalent vaccineinfluenza a virus vaccine h1n1 inactivatedinfluenza A (H1N1) 2009 pandemic monovalent vaccine